Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets

Published: September 2010
No. of Pages: 140

Price

Report Summary

THIS REPORT CONTAINS

Discussion of such disease areas as psychotherapeutics, seizure, ADHD, insomnia, migraines, and Parkinson’s
Analysis of global market trends, with data for 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015
A focus on drug classes, including selective serotonin reuptake inhibitors (SSRIs); selective norepinephrine reuptake inhibitors (SNRIs); monoamine oxidase inhibitors (MAOIs); tricyclic antidepressants (TCA); inhibition of acetylcholinesterase (AChEI) and NMDA receptors; dopamine agonists; catechol O-methyl transferase inhibitors (COMT inhibitors); and dopaminergics
A breakdown of markets by geography, including emerging markets
Comprehensive company profiles.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of central nervous system therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease sub-segments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the central nervous system sector. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with opportunity and ends with effective execution in order to capture profit.

The central nervous system therapeutic market is perhaps the most important of any drug sector. Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as serotonin and norepinephrine reuptake inhibitors (SNRIs). In contrast to technical innovation, patent expiry is producing a headwind that will cause the overall market to remain essentially flat through the forecast period.

This report analyzes emerging markets by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the period 2010 through 2015 are discussed. As well as, new products approved in 2009 and 2010 by the Federal Drug Administration (FDA), and those products expected to be approved within the forecast period. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For large markets segments such as Psychiatry, Depression, Alzheimer’s, and others, detailed disease investigation is pursued. For example, the mixing trend of increased use of selective serotonin reuptake inhibitors (SSRIs) as a first line therapy as compared to SNRIs is analyzed. For each core segment within the overall market, leading products are analyzed for their differentiation by mechanism of action.

The report includes analysis of leading and emerging competitors in the current worldwide central nervous system market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.

Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the central nervous system market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.

Excluded from this report are over the counter (OTC) medications, a detailed generics analysis, and other consumables that do not require a physician prescription.

Sales figures are reported in current U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the central nervous system market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis.
Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long term.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this report. Detailed interviews were conducted in-person and via telephone with industry participants, equity and industry analysts, leading medical physicians and other experts in the field.

Information to prepare this report was obtained from participating and emerging companies in the central nervous system market including: American Medical Association, The American Parkinson Disease Association, The National Multiple Sclerosis Society, the National Institute of Mental Health, and The American Journal of Psychiatry, Depression and Anxiety, American Parkinson Disease Association, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks, and others. Population estimates are based on those reported by the international database of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets

Table of Contents

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THE STUDY; SCOPE OF REPORT; INTENDED AUDIENCE; METHODOLOGY AND INFORMATION SOURCES; BCC ONLINE SERVICES; DISCLAIMER

CHAPTER TWO: EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)

SUMMARY FIGURE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, 2008-2015 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

CURRENT STATE OF CENTRAL NERVOUS SYSTEM DISEASE

ESTABLISHED DRUG SEGMENTS

PSYCHIATRY

DEPRESSION

MULTIPLE SCLEROSIS / PARKINSON’S

EPILEPSY/CONVULSION

ALZHEIMER’S

ATTENTION DEFICIT HYPERACTIVITY DISORDER/NARCOLEPSY

MIGRAINE

OTHER

KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM MARKET

2009 FDA PEDIATRIC ADVISORY COMMITTEE ON PRESCRIPTION OF ANTIPSYCHOTICS

GROWTH SEEN VIA PURSUIT OF ADDITIONAL INDICATIONS VERSUS NCE APPROVALS

ALZHEIMER’S DRUGS IN JAPAN OPEN UP LARGE OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT

TABLE 1 RECENTLY APPROVED AND PIPELINE FORECAST, 2009-2015 ($ MILLIONS)

CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE

TABLE 2 CENTRAL NERVOUS SYSTEM MARKET SEGMENTS: SIZE, GROWTH, SHARE ($ MILLIONS)

MARKET CONCENTRATION AND PRICE SENSITIVITY

TABLE 3 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)

MARKET TRENDS

Overall Market Flat: Higher Mix of Generics Offset by Higher Volume

Significant Impact of Patient Advocacy Groups in CNS Disease

Growth Seen via Pursuit of Additional Indications versus NCE Approvals

Improving Performance in Depression Treatments

Alzheimer’s Therapy Continues to Receive Large and Important Investment

TABLE 4 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM DRUGS, 2010 AND 2015 ($ MILLIONS)

TABLE 5 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)

TABLE 6 MARKET SHARE BY LEADING CENTRAL NERVOUS SYSTEM PLAYERS, 2010 ($ MILLIONS/%)

TABLE 7 LARGEST REVENUE GENERATING THERAPIES IN THE CENTRAL NERVOUS SYSTEM DISEASE ($ MILLIONS)

CHAPTER FIVE: MARKETS BY DISEASE

SUMMARY OF MARKET DYNAMICS

TABLE 8 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS THROUGH 2015 ($ MILLIONS)

PSYCHIATRY

MARKET DYNAMICS

TREATMENT AND MANAGEMENT

TABLE 9 CURRENT GLOBAL PSYCHIATRY MARKET, THROUGH 2010 ($ MILLIONS)

Seroquel

Zyprexa

Abilify

Geodon/Zeldox

Risperdal

TABLE 10 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($ MILLIONS)

TABLE 11 FORECAST EPIDEMIOLOGY: PSYCHIATRY

DEPRESSION

MARKET DYNAMICS

TREATMENT AND MANAGEMENT

TABLE 12 CURRENT GLOBAL DEPRESSION MARKET, THROUGH 2010 ($ MILLIONS)

Lexapro

Effexor

Cymbalta

GENERIC DRUG TRENDS: DEPRESSION

TABLE 13 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($ MILLIONS)

TABLE 14 FORECAST EPIDEMIOLOGY: DEPRESSION

MULTIPLE SCLEROSIS AND PARKINSON’S

MARKET DYNAMICS

TABLE 15 CURRENT GLOBAL MS AND PARKINSON’S MARKET, THROUGH 2010 ($ MILLIONS)

TREATMENT AND MANAGEMENT

Requip

GENERIC DRUG TRENDS: PARKINSON’S

TABLE 16 GLOBAL MS AND PARKINSON’S MARKET, THROUGH 2015 ($ MILLIONS)

TABLE 17 FORECAST EPIDEMIOLOGY: MS/PARKINSONS, THROUGH 2015

EPILEPSY/CONVULSIONS

MARKET DYNAMICS

TABLE 18 CURRENT GLOBAL EPILEPSY MARKET, THROUGH 2010 ($ MILLIONS)

TREATMENT AND MANAGEMENT

Topamax

Lyrica

Lamictal

GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS

TABLE 19 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($ MILLIONS)

ALZHEIMER’S

MARKET DYNAMICS

TABLE 20 CURRENT GLOBAL ALZHEIMER’S MARKET, THROUGH 2010 ($ MILLIONS)

TREATMENT AND MANAGEMENT

Aricept

Exelon

Namenda

TABLE 21 GLOBAL ALZHEIMER’S MARKET, THROUGH 2015 ($ MILLIONS)

GENERIC DRUG TRENDS: ALZHEIMER’S

ADHD AND NARCOLEPSY

MARKET DYNAMICS

TABLE 22 CURRENT GLOBAL ADHD / NARCOLEPSY MARKET, THROUGH 2010 ($ MILLIONS)

TREATMENT AND MANAGEMENT

Concerta

Provigil

Vyvanse

Adderall

Strattera

TABLE 23 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015 ($ MILLIONS)

GENERIC DRUG TRENDS: ADHD/NARCOLEPSY

MIGRAINE AND OTHER CNS DISEASE

MARKET DYNAMICS

TABLE 24 CURRENT GLOBAL MIGRAINE DISEASE MARKET, THROUGH 2010 ($ MILLIONS)

TABLE 25 CURRENT GLOBAL OTHER CNS DISEASE MARKET, THROUGH 2010 ($ MILLIONS)

TREATMENT AND MANAGEMENT

Ambien

Lunesta

TABLE 26 GLOBAL MIGRAINE MARKET, THROUGH 2015 ($ MILLIONS)

TABLE 27 GLOBAL OTHER CENTRAL NERVOUS SYSTEM MARKET THROUGH 2015 ($ MILLIONS)

CHAPTER SIX: MARKETS BY GEOGRAPHY

SUMMARY

TABLE 28 CURRENT MARKET SIZE BY GEOGRAPHY, THROUGH 2010 ($ MILLIONS)

METHODOLOGY

TABLE 29 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS)

UNITED STATES

TABLE 30 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: PSYCHIATRY, THROUGH 2015

TABLE 31 PEVALENCE OF EPIDEMIOLOGY IN THE U.S.: DEPRESSION, THROUGH 2015

TABLE 32 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: STROKE, THROUGH 2015

WESTERN EUROPE

TABLE 33 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: PSYCHIATRY, THROUGH 2015

TABLE 34 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: DEPRESSION, THROUGH 2015

TABLE 35 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: STROKE, THROUGH 2015

JAPAN

TABLE 36 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: PSYCHIATRY, THROUGH 2015

TABLE 37 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: DEPRESSION, THROUGH 2015

EMERGING MARKETS

STRATEGIES TO ACCESS EMERGING MARKETS

EMERGING MARKETS FORECAST

BRAZIL

Market Overview

Regulatory Considerations

Patent Considerations

TABLE 38 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: PSYCHIATRY, THROUGH 2015

TABLE 39 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: DEPRESSION, THROUGH 2015

TABLE 40 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: STROKE, THROUGH 2015

CHINA

Market Overview

Regulatory Considerations

Patent Considerations

TABLE 41 PREVALENCE OF EPIDEMIOLOGY IN CHINA: PSYCHIATRY, THROUGH 2015

TABLE 42 PREVALENCE OF EPIDEMIOLOGY IN CHINA: DEPRESSION, THROUGH 2015

TABLE 43 PREVALNCE OF EPIDEMIOLOGY IN CHINA: STROKE, THROUGH 2015

INDIA

Market Overview

Regulatory Considerations

Patent Considerations

TABLE 44 PREVALENCE OF EPIDEMIOLOGY IN INDIA: PSYCHIATRY, THROUGH 2015

TABLE 45 PREVALENCE OF EPIDEMIOLOGY IN INDIA: DEPRESSION, THROUGH 2015

TABLE 46 PREVALENCE OF EPIDEMIOLOGY IN INDIA: STROKE, THROUGH 2015

RUSSIA

Market Overview

Regulatory Considerations

Patent Considerations

TABLE 47 PEVALENCE OF EPIDEMIOLOGY IN RUSSIA: PSYCHIATRY, THROUGH 2015

TABLE 48 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: DEPRESSION, THROUGH 2015

TABLE 49 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: STROKE, THROUGH 2015

SOUTH AMERICA

TABLE 50 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: PSYCHIATRY, THROUGH 2015

TABLE 51 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: DEPRESSION, THROUGH 2015

TABLE 52 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: STROKE, THROUGH 2015

CARIBBEAN

TABLE 53 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: PSYCHIATRY, THROUGH 2015

TABLE 54 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: DEPRESSION, THROUGH 2015

TABLE 55 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: STROKE, THROUGH 2015

NORTHERN EUROPE

TABLE 56 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: PSYCHIATRY, THROUGH 2015

TABLE 57 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: DEPRESSION, THROUGH 2015

TABLE 58 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: STROKE, THROUGH 2015

CENTRAL AND EASTERN EUROPE

TABLE 59 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: PSYCHIATRY, THROUGH 2015

TABLE 60 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: DEPRESSION, THROUGH 2015

TABLE 61 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: STROKE, THROUGH 2015

AUSTRALIA

TABLE 62 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: PSYCHIATRY, THROUGH 2015

TABLE 63 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: DEPRESSION, THROUGH 2015

TABLE 64 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: STROKE, THROUGH 2015

ASIA-OTHER

TABLE 65 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: PSYCHIATRY, THROUGH 2015

TABLE 66 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: DEPRESSION, THROUGH 2015

TABLE 67 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: STROKE, THROUGH 2015

MIDDLE EAST

TABLE 68 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: PSYCHIATRY, THROUGH 2015

TABLE 69 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: DEPRESSION, THROUGH 2015

TABLE 70 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: STROKE, THROUGH 2015

SOUTHERN AFRICA

TABLE 71 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: PSYCHIATRY, THROUGH 2015

TABLE 72 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: DEPRESSION, THROUGH 2015

TABLE 73 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: STROKE, THROUGH 2015

AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST

CHAPTER SEVEN: PIPELINE ANALYSIS

TABLE 74 APPROVED PRODUCT FORECAST, 2009-2015 ($ MILLIONS)

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT

KEY TRENDS IN RESEARCH AND DEVELOPMENT

SNRIs Improve the Baseline Performance of Leading Depression Therapies

New Products Provide Larger Opportunities Compared to Product Extensions

Combination Products Yield Greater Therapeutic Response

Alzheimer’s Therapy Continues to Receive Large and Important Investment

KEY PRODUCTS UNDER MAJOR CNS DISORDERS

Schizophrenia

Depression

Alzheimer’s

Parkinson’s Disease

Epilepsy

Insomnia

Attention Deficit Hyperactivity Disorder

Other Indications

2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY

PHASE III AND PENDING APPROVAL COMPOUNDS

Bapineuzumab (AAB-001)—Elan/Wyeth/Pfizer

TABLE 75 BAPINEUZUMAB (AAB-001)—ELAN/WYETH/PFIZER

Telcagepant (MK-0974)—Merck

TABLE 76 TELCAGEPANT (MK-0974)—MERCK

Solanezumab (LY2062430)—Eli Lilly

TABLE 77 SOLANEZUMAB (LY2062430)—ELI LILLY

Semagacestat (LY450139)—Eli Lilly

TABLE 78 SEMAGACESTAT (LY450139)—ELI LILLY

Vilazodone—Clinical Data

TABLE 79 VILAZODONE—CLINICAL DATA

RECENTLY APPROVED/MARKETED DRUGS

Stedesa/Zebinix (eslicarbazepine acetate)—Dainippon Sumitomo (formerly Sepracor)

TABLE 80 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE)—DAINIPPON SUMITOMO (FORMERLY SEPRACOR)

Intuniv (guanfacine)—Shire

TABLE 81 INTUNIV (GUANFACINE)—SHIRE

Treximet (Sumatriptan and Naproxen)—GSK/Pozen

TABLE 82 TREXIMET (SUMATRIPTAN AND NAPROXEN)—GSK/POZEN

Pristiq (desvenlafaxine)—Pfizer/Wyeth

TABLE 83 PRISTIQ (DESVENLAFAXINE)—PFIZER/WYETH

Vimpat (lacosamide)—UCB/Schwarz Pharma

TABLE 84 VIMPAT (LACOSAMIDE)—UCB/SCHWARZ PHARMA

TABLE 85 DEVELOPMENTAL PRODUCT FORECAST, 2009-2015 ($ MILLIONS)

CHAPTER EIGHT: COMPANY PROFILES

SUMMARY

TABLE 86 COMPANY REVENUE AND MARKET SHARE ANALYSIS, THROUGH 2010 ($ MILLIONS)

TABLE 87 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS)

COMPANIES

ABBOTT LABORATORIES

Business Overview

Therapeutic Areas

TABLE 88 ABBOTT LABORATORIES’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

ALLERGAN, INC.

Business Overview

Therapeutic Areas

TABLE 89 ALLERGAN’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

Business Overview

Therapeutic Areas

TABLE 90 ASTELLAS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

ASTRAZENECA

Business Overview

Therapeutic Areas

TABLE 91 ASTRAZENECA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

BAYER AG

Business Overview

Therapeutic Areas

TABLE 92 BAYER HEALTHCARE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

BIOGEN IDEC (FUMAPHARM AG)

Business Overview

Therapeutic Areas

TABLE 93 BIOGEN’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

ELI LILLY & CO.

Business Overview

Therapeutic Areas

TABLE 94 ELI LILLY’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

FOREST LABORATORIES, INC.

Business Overview

Therapeutic Areas

TABLE 95 FOREST LABORATORIES’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

GLAXOSMITHKLINE (GSK)

Business Overview

Therapeutic Areas

TABLE 96 GLAXOSMITHKLINE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

JOHNSON & JOHNSON

Business Overview

Therapeutic Areas

TABLE 97 JOHNSON & JOHNSON’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

MERCK & CO., INC.

Business Overview

Therapeutic Areas

TABLE 98 LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

Business Overview

Therapeutic Areas

TABLE 99 NOVARTIS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

PFIZER, INC.

Business Overview

Therapeutic Areas

TABLE 100 PFIZER’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

SANOFI-AVENTIS

Business Overview

Therapeutic Areas

TABLE 101 SANOFI-AVENTIS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

SHIRE PHARMACEUTICALS GROUP, PLC

Business Overview

Therapeutic Areas

TABLE 102 SHIRE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

Business Overview

Therapeutic Areas

TABLE 103 TAKEDA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

TEVA PHARMACEUTICAL INDUSTRIES LTD

Business Overview

Therapeutic Areas

TABLE 104 TEVA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

WATSON PHARMACEUTICALS, INC.

Business Overview

Therapeutic Areas

TABLE 105 WATSON’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS)

Corporate Strategy

LIST OF TABLES